Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany

Respiratory Medicine

Volumn 103, Issue 12, 2009, Pages 1838-1853

  Diel, R ^a   Schaberg, T ^b   Loddenkemper, R ^c   Welte, T ^a   Nienhaus, A ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Deaconess Hospital Rotenburg   (Germany)

^c German Central Committee Against Tuberculosis   (Germany)

^d Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services   (Germany)

Author keywords

Contact investigation; Cost benefit; Interferon release assay; Isoniazid preventive treatment; Latent tuberculosis infection; Tuberculosis

Indexed keywords

ISONIAZID;

ARTICLE; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; GERMANY; INTERMETHOD COMPARISON; LIVER TOXICITY; LUNG TUBERCULOSIS; PRIORITY JOURNAL; QUANTIFERON TB GOLD IN TUBE TEST; SCREENING; SENSITIVITY ANALYSIS; TUBERCULIN TEST;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; EPIDEMIOLOGIC METHODS; GERMANY; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; TUBERCULIN TEST;

EID: 70350721784     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.07.008     Document Type: Article

References (39)

1. Diel R., Loddenkemper R., Meywald-Walter K., Niemann S., and Nienhaus A. Predictive value of a whole-blood IFN-γ assay for the development of active TB disease. Am J Respir Crit Care Med 177 (2008) 1164-1170
2. Chisholm D., and Evans D. Economic evaluation in health: saving money or improving care?. J Med Econ 10 (2007) 325-337
3. Diel R., Forssbohm M., Loytved G., et al. Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis. Pneumologie 58 (2007) 657-665
4. Claxton K., Sculpher M., McCabe C., et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14 (2005) 339-347
5. Fryback D.G., Chinnis J.O., and Ulvila J.W. Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Int J Technol Assess Health Care 17 (2001) 83-97
6. De Perio M.A., Tsevat J., and Roselle G.A. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 169 (2009) 179-187
7. Marra F., Marra C.A., and Sadatsafavi M. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 12 (2008) 1414-1424
8. Salpeter S.R., and Salpeter E.E. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculisis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 25 (2004) 1056-1061
9. Wrighton-Smith P., and Zellweger J.-P. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 28 (2006) 45-50
10. Sahni R., Miranda C., and Yen-Lieberman B. Does the implementation of an interferon-g release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?. Infect Control Hosp Epidemiol 30 (2009) 197-199
11. Ferebee S.H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 17 (1970) 28-106
12. Doubilet P., Begg C.B., Weinstein M.C., Braun P., and McNeil B.J. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 5 (1985) 157-177
13. Hutubessy R.C.W., Baltussen R.M.P.M., Evans D.B., Barendregt J.J., and Murray C. Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ 10 (2001) 473-477
14. Menzies D., Dion M.J., Rabinovitch B., Mannix S., Brassard P., and Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170 (2004) 445-449
15. Bock N.N., Metzger B.S., Tapia J.R., and Blumberg H.M. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. AJRCCM 159 (1999) 295-300
16. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 134 (1986) 355-363
17. Scharer L., and Smith J.P. Serum transaminase elevations and other hepativ abnormalities in patients receiving isoniazid. Ann Intern Med 71 (1969) 1113-1120
18. Steele M.A., Burk R.F., and DesPrez R.M. Toxic hepatitis with isoniazid and rifampin - a meta-analysis. Chest 99 (1991) 465-471
19. Smieja M.J., Marchetti C.A., Cook D.J., and Smaill F.M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1 (1999) 10.1002/14651858.CD001363 Art. No.: CD001363
20. Thompson N.J. International Union Against Tuberculosis committee on prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 60 (1982) 555-564
21. Kopanoff D.E., Snider D.E., and Caras G.J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117 (1978) 991-1001
22. Millard P.S., Wilcosky T.C., Reade-Christopher S.J., and Weber D.J. Isoniazid related fatal hepatitis. West J Med 164 (1996) 486-491
23. Nolan C.M., Goldberg S.V., and Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281 (1999) 1014-1018
24. Salpeter S.R. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 159 (1993) 560-564
25. Snider D.E., and Caras G.J. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 145 (1992) 494-497
26. Lo Bue P.A., and Moser K.S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168 (2003) 443-447
27. Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 3 (1999) 847-850
28. Egsmose T., Ang'awa J.O.W., and Poti S.J. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 33 (1965) 419-433
29. John G.T., Thomas P.P., Thomas M., Jeyaseelan L., Jacob C.K., and Shastry J.C.M. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 57 (1994) 1683-1684
30. Ferebee S.H., and Mount F.W. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 85 (1962) 490-510
31. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2006, Berlin; 2008.
32. Salpeter S.R., Sanders G.D., Salpeter E.E., and Owens D.K. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk benefit and cost-effectiveness analysis. Ann Intern Med 127 (1997) 1051-1061
33. Diel R., Rappenhöner B., and Schaberg T. The cost structure of lung tuberculosis in Germany. Eur J Health Econ 5 (2004) 243-251
34. Gesundheitsberichterstattung des Bundes. Diagnosedaten der Krankenhäuser ab 2000 (Eckdaten der vollstationären Patienten und Patientinnen). http://www.gbe-bund.de
35. Einheitlicher Bewertungsmaßstab. EBM, Kassenärztliche Bundesvereinigung. http://www.kbv.de/8170.html
36. Schulenburg J.M., Greiner W., Jost F., et al. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens. Gesundh ökon Qual mang 12 (2007) 285-290
37. Statistisches Bundesamt. Volkswirtschaftliche Gesamtrechungen; Fachserie 18, Reihe 1.2 2. Vierteljahr 2008, 2.15 Lohnkosten je Arbeitnehmer. Wiesbaden; 2008.
38. Gesundheitsberichterstattung des Bundes. Arbeitsunfähigkeit bei AOK-Pflichtmit-gliedern ohne Rentner (Arbeitsunfähigkeitsfälle und Arbeitsunfähigkeitstage, Tage je Fall). Jahr (2007)
39. Diel R., Nienhaus A., Lange C., and Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 28 (2006) 35-44